Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Taminadenant - Novartis/Palobiofarma

Drug Profile

Taminadenant - Novartis/Palobiofarma

Alternative Names: NIR 178; PBF-509

Latest Information Update: 27 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palobiofarma
  • Developer Novartis; Palobiofarma
  • Class Amines; Antineoplastics; Antiparkinsonians; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Adenosine A2A receptor antagonists; Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Solid tumours
  • Phase I/II Non-small cell lung cancer
  • Phase I Breast cancer; Cancer
  • No development reported Attention-deficit hyperactivity disorder; Lung cancer; Parkinson's disease

Most Recent Events

  • 26 Sep 2019 XOMA and Palobiofarma enter into an agreement for royalty interest for adenosine pathway
  • 28 Jun 2019 No recent reports of development identified for phase-I development in Lung-cancer in Spain (PO, Capsule)
  • 31 Jan 2019 Phase-I clinical trials in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy, Japan, Hong Kong, Netherlands, USA, Australia, Spain (PO) (NCT03742349)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top